deepull Closes €50 Million Series C to Boost Detection Technology

deepull Secures €50 Million in Oversubscribed Series C Financing

deepull, an innovative medical diagnostics company, has successfully closed an oversubscribed Series C financing round, raising a remarkable €50 million to advance its UllCORE diagnostic system aimed at rapid pathogen detection directly from blood samples.

Key Investors Backing the Funding

This significant funding round was co-led by noted investors including Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners. Their commitment to deepull's vision highlights the growing confidence in the potential of breakthrough diagnostic technologies. The financing saw robust participation from existing investors such as Asabys Partners, Innvierte-CDTI, and others, underscoring the interest in innovative healthcare solutions.

Deployment of Funds and Clinical Validation

The proceeds from this financing will be directed towards finalizing the clinical validation of deepull’s UllCORE diagnostic system, which is poised to revolutionize the way bloodstream infections are diagnosed. This system has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration, reflecting its promise in the medical field.

UllCORE employs advanced molecular techniques for detecting and extracting microbial DNA directly from whole blood, minimizing the time required to identify pathogens. Practitioners can expect critical results within an hour, vastly improving the current standard that often requires days of waiting for blood culture test results.

Addressing the Urgent Challenge of Sepsis Diagnosis

Sepsis remains a leading cause of hospital deaths globally, with dire implications for healthcare systems. It causes or contributes to one out of every three hospital fatalities in the U.S., and septic shock carries an alarmingly high mortality rate. This urgent need for rapid diagnosis and treatment emphasizes the importance of deepull’s innovative approach.

Historically, diagnosing bloodstream infections has been complicated and time-consuming. The symptoms of sepsis are often vague and difficult to recognize, making swift and accurate diagnosis vital for patient survival.

Leadership Insights on the Financing

Jordi Carrera, CEO of deepull, expressed his enthusiasm regarding this critical financing milestone: "This financing marks a critical step forward for deepull as we move towards completing the clinical studies of our diagnostic system. With this support, we are poised to deliver a transformative diagnostic solution to healthcare providers and patients worldwide."

Rick Ivey, Chairman of the Board of Directors at deepull, underlined the overwhelming support from investors, stating, "The strong support and oversubscription in this financing round reflect both the strength of deepull's technology and its potential to redefine diagnostic standards."

Industry Support for deepull’s Vision

Industry leaders have expressed confidence in deepull’s trajectory. Alessio Piuma from Panakès Partners remarked, "We searched at length for an optimal solution in the sepsis space and we are extremely glad to support deepull. Its promising UllCORE system has the potential to overcome the serious challenges faced by clinicians in the diagnosis of sepsis. "

Moreover, Jose Mesa from Columbus Venture Partners emphasized their commitment, stating, "We are thrilled to support deepull's vision as it transitions towards commercialization to impact the management of patients with sepsis." Valérie Calenda from Mérieux Equity Partners also noted her excitement for the technology, indicating a shared investment in its potential impact on healthcare.

About deepull and Its Innovations

deepull is dedicated to developing cutting-edge, culture-free diagnostic solutions for sepsis and acute infections. The company is currently focusing on the UllCORE BSI Test, designed to target 95% of pathogens causing sepsis. The test effectively extracts total microbial DNA from just 8mL of blood, generating 52 reportable results. Its automation capabilities are designed to fulfill the needs of any clinical laboratory, enhancing efficiency and patient care.

Frequently Asked Questions

What funding did deepull secure recently?

Deepull secured €50 million in an oversubscribed Series C financing round.

Who led the financing round?

The round was co-led by Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners.

What is the UllCORE diagnostic system?

The UllCORE system is a diagnostic technology designed for rapid pathogen detection from blood samples, providing results in about an hour.

What is the significance of Breakthrough Device Designation?

This designation reflects the U.S. FDA's recognition of the UllCORE system's potential to greatly improve patient diagnosis and outcomes.

How does deepull contribute to sepsis treatment?

Deepull offers innovative solutions for diagnosing sepsis faster and more accurately, which can save lives and improve patient care.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.